Less Ads, More Data, More Tools Register for FREE

Pin to quick picksASLR.L Regulatory News (ASLR)

  • There is currently no data for ASLR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further re:- Suspension

4 Mar 2020 09:15

RNS Number : 9823E
Asimilar Group PLC
04 March 2020
 

4 March 2020

 

 

Asimilar Group plc

("Asimilar" or the "Company")

 

Further re:- Suspension

 

 

Further to the announcement of 14 February 2020 in relation to the temporary suspension of the Company's shares from trading on AIM, the Company makes the following update.

 

The Company continues its discussions with Sentiance NV ("Sentiance"), a leading player in artificial intelligence ("AI"), machine learning and contextual behavioural data science, and intends to publish an admission document and to convene a General Meeting seeking shareholder approval for the readmission of the Company's shares to trading on AIM.

 

Subject to regulatory consents, the Company will seek shareholder approval to subscribe for 10,000 new Sentiance shares at a price of €750 per share for an aggregate consideration of €7,500,000 ("Initial Investment"). The Initial Investment would represent circa 9.3% of the enlarged share capital of Sentiance.

 

In addition, the Company would be granted an option to purchase 32,225 existing Sentiance shares at an exercise price of €650 per share ("Option 1") and a further option to subscribe for 10,000 new shares in Sentiance at an exercise price of €750 per share ("Option 2"). Shareholder consent would also be sought to enter into both Option 1 and Option 2.

 

Following the Initial Investment and assuming both Option 1 and Option 2 were exercised the Company would have an interest over circa 44.5% of Sentiance's so enlarged issued share capital, assuming no other Sentiance shares were issued, but is currently expected to have an aggregate interest of nearer 35.9% following the anticipated issue of further Sentiance shares to a third party and the exercise of share options by management and staff.

 

Due to the aggregate size of the proposed investment and the options relative to the Company's existing portfolio, the proposal will be classified as a reverse takeover under the AIM Rules and therefore will be conditional, inter alia, upon the approval of shareholders.

 

The Board confirms that the Company's shares will continue to be suspended pursuant to AIM Rule 40 pending the publication of an admission document with further details in relation to the proposed investments and fundraise, however, there is no guarantee that any definitive agreement will be reached with Sentiance.

Further announcements will be made in due course.

 

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

**ENDS**

Enquiries

Asimilar Group plc

John Taylor, Non-Executive Chairman

via Buchanan

Cairn Financial Advisers LLP

Sandy Jamieson, Liam Murray

Tel: +44 20 7213 0880

Peterhouse Capital Limited

Duncan Vasey / Lucy Williams

Tel: + 44 20 7220 9797

Buchanan Communications Limited

Richard Oldworth / Chris Lane

Tel: +44 (0) 20 7466 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURKKQBDCBKKNNK
Date   Source Headline
23rd Jun 20087:00 amRNSInterim Results
9th Jun 200812:00 pmRNSContract Win
19th Mar 20082:29 pmRNSDirector/PDMR Shareholding
17th Mar 20082:22 pmRNSPosting of annual report
29th Feb 20087:01 amRNSContract gains
27th Feb 20089:27 amRNSHolding(s) in Company
26th Feb 20081:58 pmRNSDirector/PDMR Shareholding
25th Feb 20082:21 pmRNSAGM Statement
6th Feb 20087:01 amRNSAdditional Listing & Placing
31st Jan 20083:35 pmRNSFinal Results
6th Nov 20075:40 pmRNSDirectorate Change
15th Oct 20077:00 amRNSBlue chips trial product
8th Oct 20077:01 amRNSSignificant contract gain
28th Sep 20077:02 amRNSContract Gains
21st Sep 20077:01 amRNSSignificant contract gain
10th Sep 20077:02 amRNSPrivate Placing
17th Aug 20079:07 amRNSRule 26 compliance
13th Aug 20077:00 amRNSContract gains
6th Aug 20077:00 amRNSNew distributor
29th Jun 20077:01 amRNSInterim Results
22nd Jun 20077:01 amRNSContract gains
15th Jun 20077:01 amRNSContract gain
23rd May 20077:01 amRNSBoard Change
14th May 200711:22 amRNSAGM Statement
11th May 20077:01 amRNSNew product launch
23rd Apr 20077:02 amRNSAppointment of Distributors
20th Apr 20075:47 pmRNSDirector/PDMR Shareholding
19th Apr 20077:01 amRNSContract gain
4th Apr 20077:03 amRNSGrowing presence in the USA
29th Mar 200712:15 pmRNSFinal Results
19th Jan 200711:29 amRNSTotal Voting Rights
22nd Dec 200610:06 amRNSTotal Voting Rights
6th Dec 20066:41 pmRNSIssue of Equity
10th Nov 20067:00 amRNSRe Contract
3rd Nov 20067:00 amRNSRe Contract
27th Oct 20067:01 amRNSRe Contract
26th Sep 20061:10 pmRNSIssue of Equity
22nd Sep 20067:00 amRNSContract wins
31st Jul 20067:00 amRNSContract gain
24th Jul 20067:01 amRNSInvestment
15th Jun 20063:05 pmRNSIssue of Equity
14th Jun 20067:01 amRNSInterim Results
6th Jun 20067:01 amRNSContract gain
15th May 200611:37 amRNSDisposal
18th Apr 20067:01 amRNSBoard changes
31st Mar 20063:36 pmRNSAnnual Report and Accounts
31st Mar 200610:37 amRNSFinal Results
24th Feb 20067:00 amRNSCompany Restructure
8th Dec 20057:00 amRNSBahrain office & contract win
25th Nov 20057:00 amRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.